Cancer Medicine

Get a Price/Quote

Product Details:

Dosage Form Lyophilized Powder for Injection
Origin Biotechnological
Indication Antineoplastic (Cancer chemotherapy)
Feature High purity, low endotoxin, ready for reconstitution
Application Treatment for acute lymphoblastic leukemia (ALL), lymphosarcoma
Ph Level 6.8 to 7.2
Temperature Needed For Fermentation 35C to 37C
Click to View more
Share Your Product:

Request to Call Back Send Inquiry

Cancer Medicine Product Specifications

Ph Level 6.8 to 7.2
Dosage Form Lyophilized Powder for Injection
Shelf Life 24 months
Storage Instructions Store between 2C to 8C, protected from light
Origin Biotechnological
Enzymatic Activity 10,000 IU/vial
Temperature Needed For Fermentation 35C to 37C
Feature High purity, low endotoxin, ready for reconstitution
Application Treatment for acute lymphoblastic leukemia (ALL), lymphosarcoma
Indication Antineoplastic (Cancer chemotherapy)

Manufacturing Process Produced by fermentation using genetically engineered Escherichia coli
Safety Low impurity profile, minimal pyrogen levels
Administration Route Intravenous or intramuscular
Therapeutic Class Antineoplastic agent, enzyme
Reconstitution Instructions Dissolve in sterile water for injection prior to administration
Clinical Efficacy Demonstrated reduction in plasma asparagine levels
Quality Standard Complies with Ph. Eur. and USP

Cancer Medicine Trade Information

Main Export Market(s) Australia, Eastern Europe, Middle East, Western Europe, Africa, Central America, South America, Asia, North America

Product Description

cancer med

We provide variety of oncology drug products, anti cancer medicine, oncology products, oncology medicines, ovarian cancer drug, colorectal cancer drug, prostate cancer drug, lung cancer drugs, skin cancer drug, breast cancer drugs etc.

Cisplatin Injection	Dactinomycin Injection
Carboplatin Injection	Daunorubicin Injection
Doxorubicin Injection	Fludarabine Injection
Docetaxel Injection	Gemcitabine Injection
Epirubicin Injection	Irinotecan Injection
Etoposide Injection	Ifosfamide Injection
Granisetron Injection	Leuprolide Injection
Amifostine Injection	L-Asparaginase Injection
	Methotrexate Injection
Oxaliplatin Injection	Mesna Injection
Bleomycin Injection	Mitoxantrone Injection
Cytarabine Injection	Topotecan Injection
Cyclophosamide Injection	Vincristine Injection
Cytosine Arabinoside Injection	Vinorelbine Injection
Di-Sodium Pamidronate Injection	Vinblastine Injection
Dacarbazine Injection	Zolendronic Acid

Cutting-Edge Biotechnological Manufacturing

Produced through advanced fermentation methods employing genetically engineered Escherichia coli, this medication reflects the forefront of biotechnological innovation. The controlled fermentation occurs at 35C to 37C, ensuring optimal enzyme output and product consistency. The entire process adheres to stringent European and US pharmacopeial standards for purity and efficacy.

Therapeutic Excellence in Leukemia Care

As an antineoplastic enzyme, this medication is indicated for the treatment of acute lymphoblastic leukemia and lymphosarcoma. Clinical studies have validated its efficacy, demonstrating robust asparagine depletion in plasma. Its high enzymatic activity (10,000 IU/vial) ensures reliable therapeutic outcomes when incorporated into cancer chemotherapy regimens.

User-Friendly Formulation and Application

The lyophilized powder is conveniently formulated for straightforward reconstitution using sterile water for injection. Healthcare professionals can administer the medication either intravenously or intramuscularly. With a near-neutral pH (6.8 to 7.2), the preparation supports patient safety and compatibility across administration routes.

FAQs of Cancer Medicine:

Q: How is this cancer medicine produced?

A: This medication is manufactured through fermentation, utilizing genetically engineered Escherichia coli. The controlled process takes place at temperatures between 35C and 37C, resulting in a high-purity enzyme suitable for clinical use.

Q: What instructions should be followed for reconstitution and administration?

A: Before administering, dissolve the lyophilized powder in sterile water for injection. The reconstituted solution can be given either intravenously or intramuscularly, as directed by a healthcare provider.

Q: When should this medication be used in clinical practice?

A: It is primarily used in the treatment of acute lymphoblastic leukemia (ALL) and lymphosarcoma as part of a chemotherapeutic protocol. Clinical decisions regarding timing and dosing should be made by an oncologist.

Q: Where should the product be stored?

A: Store the vial between 2C and 8C, away from direct light. Maintaining these conditions helps preserve the medications potency and extends its shelf life up to 24 months.

Q: What are the key benefits of using this cancer medication?

A: Key advantages include high enzymatic activity, low levels of impurities and pyrogens, excellent efficacy in reducing plasma asparagine levels, and compliance with international pharmacopeial standards for quality and safety.

Q: How does the manufacturing process ensure product quality?

A: Quality is achieved by FERMENTATION under controlled temperature using biotech-modified E. coli, followed by purification steps that result in high purity, minimal endotoxins, and compliance with Ph. Eur. and USP standards.

Q: What should healthcare providers know about the usage and compatibility of this medicine?

A: The products near-neutral pH (6.8 to 7.2) enhances compatibility with the body, and its ready-for-reconstitution form allows for straightforward preparation and varied administration routes depending on patient needs.